MA-RHINOSTICS
Safeguard DNA Diagnostics Inc, SDDI, one of the largest chains of infectious disease laboratories in the Philippines, has introduced COVID sample collection using the Rhinosticsᵗᵐ dry nasal and nasopharyngeal collection swabs. The dry swabs are being introduced at its facilities in Metro Manila, Davao and Negros Occidental. In addition, SDDI will act as the exclusive distributor of Rhinostics in the Philippines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005070/en/
Rhinostics Inc. is a Harvard University spinout company launched to bring new materials and designs for improved sample collection for COVID and broader non-COVID respiratory testing. The Rhinosticsᵗᵐ swabs received a U.S. Emergency Use Authorization (EUA) for COVID sample collection. These swabs allow more comfortable collection, dry shipment and transport without viral transport media.
Paul Jochico, co-Founder and Director of Safeguard DNA Diagnostics, Inc. commented, “We are excited to bring the Rhinostics’ innovative sample collection swabs to the Philippines, to offer our people a more comfortable collection combined with strong assay performance. The dry swabs are more robust and offer lower risk for contamination during collection and transport than VTM and saliva collection devices. Continued COVID testing will help keep more people safe until vaccinations can become widespread in the Philippines.”
George Aaron, CEO and Chairman of Safeguard Biosystems Holdings Ltd, the joint venture partner in SDDI, remarked, “The opportunity to repurpose our molecular microbiology laboratory in Manila provided significant benefits to the people of the Philippines during this unfortunate pandemic. Safeguard remains committed to bringing innovative products for the diagnosis of infectious disease into SDDI’s operations.”
“We could not ask for a better partner to implement our collection swab technology in the Philippines, bringing the newest technology for dry collection, transport and assay performance to the country. SDDI remains an innovator in the diagnostics space in the Philippines, bringing newest technologies to market,” said Cheri Walker, Chief Executive Officer of Rhinostics.
About Safeguard DNA Diagnostics, Inc
Safeguard DNA Diagnostics Inc. (SDDI) is a Philippine Joint Venture company with an equal partnership between Safeguard Biosystems and the interests of Paul Jochico, established to provide Molecular Microbiology diagnostic laboratory services. It delivers rapid detection and identification to COVID-19 and other infectious diseases for the Philippine population.
About Safeguard Biosystems
Safeguard Biosystems is an international molecular diagnostics group that has developed a low cost, high-throughput, molecular diagnostic technology platform. The system enables rapid identification by DNA of the most prevalent bacterial and fungal pathogens directly from blood. Clinical samples can be tested from matrices such as whole blood, urine, peritoneal fluid, and swabs
Safeguard Biosystems is a UK company, incorporated in 2006 and headquartered in Northvale, New Jersey. Safeguard Biosystems’ technology has also been adapted to provide innovative pathogen solutions for Dairy, delivering practical solutions for advanced dairy industry challenges to ensure safe dairy food and healthy herds.
About Rhinostics Inc.:
Rhinostics commercializes simple and elegant solutions to bring better materials, efficiencies and cost savings to the laboratory workflow. The RHINOstic™ automated nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube and rapid accessioning using the 2D barcode on the bottom of the tubes. The product provides an immediate impact to increasing COVID testing efficiencies while being applicable to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction (PCR) and next generation sequencing (NGS). In addition, the company offers both a standard nasal swab and nasopharyngeal swab that allow dry shipment, sample concentration and better assay performance. The Rhinostics suite of collection products are registered as Class I exempt medical devices with the FDA and are available for purchase. To learn more, visit https://www.rhinostics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005070/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
Primient to Acquire Full Ownership of Primient Covation, LLC14.1.2026 16:00:00 CET | Press release
Primient, a global leader in biomanufacturing, announced today it has agreed to purchase the remaining ownership interest in Primient Covation, LLC (“Primient Covation”), establishing Primient as the sole owner of the company and marking an exciting new chapter in Primient’s growth in the bioeconomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114344080/en/ This acquisition is the next step of Primient’s strategy to strengthen Primient’s leadership position in biomanufacturing and builds upon recent announcements, including Primient’s partnership with Sustainea and the creation of the iPROOF venture. Primient Covation stands as a leading force in the U.S. biomanufacturing sector, distinguished by its broad range of biomanufacturing and fermentation expertise. The company was founded in 2000 to supply a variety of end markets, including cosmetics and personal care, textiles, fashion, coatings, functional fluids, and oth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom